The majority of promotional expenditures are invested in drug samples, one of the industry’s most important marketing tactics ...

In late August 2025, CMS released Performance Year (PY) 2024 data for the Medicare Shared Savings Program (MSSP). This marked ...

The Inflation Reduction Act (IRA) of 2022 mandates price negotiations for certain drugs under Medicare, shortening the exclusivity period historically used to recoup research and development ...

Audrey Ford, MS, is a Policy Research Associate on the Health Care Transformation team at Duke-Margolis and supports projects on the Medicare accountable care portfol ...

Merna Shohdy is a medical student at the City University of New York School of Medicine and an affiliated researcher at Memorial Sloan Kettering Cancer Center.

Despite Medicaid’s importance as a payer and source of coverage for mental health care, relatively little is known about how prevalence, access, and quality might vary among Medicaid beneficiaries.

When the sole manufacturer withdrew a critical cancer drug from Medicare and Medicaid, patients were left without options.

The 340B rebate pilot model set to begin in January 2026 starkly presents the key tradeoff between program integrity and ...

The real gold standard for science, and academic freedom, requires upholding scientific work that investigates who and what ...

The No UPCODE Act—with some refinements—is a good start insofar it establishes some key pieces of reform, but a broader ...

Gita Deo is a healthcare strategist with a career spanning federal policy, healthcare administration, and consulting. She currently serves as Chief of Staff at the CMS Innovation Center, where she ...

With collaboration and evidence-based approaches, we can build a patient-centric health care system that works better for ...